Program
zavegepant
Also written as “Zavegepant”, “Zavegepant (BHV-3500)” and “Zavegepant 10 mg IN”.
Its studies are mostly in Migraine Disorders · Asthma · COVID-19, led by Pfizer.
Furthest: phase 3, since Mar 6, 201913 company-led studies, 1 open or runningNext primary completion: Aug 12, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 131 open or running | phase 3since Mar 6, 2019 | Mar 6, 2019 | Aug 12, 2027phase 1 · NCT06995729 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 6, 2019First study: phase 3 study in Migraine DisordersFirst studyNCT03872453 · 2,154 enrolled · United States
- Apr 9, 2020Phase 3 study in COVID-19NCT04346615 · 47 enrolled · United States
- May 26, 2020Phase 3 study in Migraine DisordersNCT04408794 · 974 enrolled · United States
- Sep 11, 2020Phase 3 study in Migraine DisordersNCT04571060 · 1,978 enrolled · United States
- Mar 5, 2021Phase 3 study in Migraine DisordersNCT04804033 · 1,753 enrolled · United States
- Jul 26, 2021Phase 1 study in AsthmaNCT04987944 · 45 enrolled · Canada
- Jul 7, 20232 phase 1 studiesNCT05948085, NCT05960032
- Aug 3, 2023Phase 3 study in Migraine DisordersNCT05989048 · 1,414 enrolled · China, South Korea, Taiwan
- Oct 6, 2023Phase 3 study in Migraine DisordersNCT06103734
- Nov 14, 2023Phase 1 study in Biological AvailabilityNCT06137703 · 52 enrolled · United States
- May 28, 2024Phase 1 study in HealthyNCT06453356 · 12 enrolled · United States
- May 7, 2025Phase 1 study in Migraine DisordersNCT06995729 · 16 planned · United States
Ahead
- Aug 12, 2027Primary completion: phase 1 study in Migraine DisordersNCT06995729
TargetBeta
“A highly soluble small molecule calcitonin gene related peptide (CGRP) receptor antagonist, ”NCIt, by rule
“Calcitonin-gene-related peptide receptor, CALCRL/RAMP1 antagonist; Calcitonin gene-related peptide type 1 receptor antagonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| atogepantrule | AbbVie | phase 4 | 19 |
| ubrogepantrule | AbbVie | phase 4 | 13 |
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06995729Migraine Disorders · United States | 1 | Recruiting | Aug 12, 2027 | 16 |
| NCT06453356Healthy · United States | 1 | Completed | Sep 26, 2024 | 12 |
| NCT06137703Biological Availability · United States | 1 | Completed | Dec 7, 2022 | 52 |
| NCT06103734Migraine Disorders | 3 | Withdrawn | Aug 2, 2027 | 0 |
| NCT05989048Migraine Disorders · China, South Korea, Taiwan | 3 | Completed | May 30, 2025 | 1,414 |
| NCT05960032Healthy · China | 1 | Completed | Dec 12, 2023 | 13 |
| NCT05948085Migraine Disorders · United States | 1 | Completed | Sep 5, 2023 | 14 |
| NCT04987944Asthma · Canada | 1 | Terminated | Mar 29, 2023 | 45 |
| NCT04804033Migraine Disorders · United States | 3 | Terminated | Mar 21, 2024 | 1,753 |
| NCT04571060Migraine Disorders · United States | 3 | Completed | Oct 10, 2021 | 1,978 |
| NCT04408794Migraine Disorders · United States | 3 | Completed | Dec 9, 2021 | 974 |
| NCT04346615COVID-19 · United States | 3 | Terminated | Apr 29, 2022 | 47 |
| NCT03872453Migraine Disorders · United States | 3 | Completed | Oct 31, 2019 | 2,154 |
How it is read
Names in the registry
- “Zavegepant”, 6 entries
- “Zavegepant (BHV-3500)”, 2 entries
- “Zavegepant 10 mg IN”, 1 entry
- “Zavegepant 10 mg”, 1 entry
- “BHV-3500 (zavegepant)”, 1 entry
Conditions, from the studies’ own filings
- Migraine Disorders, 8 studies
- Asthma, 1 study
- COVID-19, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.